

5 July 2023

## Incidence and treatment of breast cancer

- Information as available from RISOH (regional information system Oncology/Haematology) February - April 2023.
- Please note: Aromatase Inhibitors Prescribed via GP therefore information not available via RISOH query field. Figure supplied for main regimen.
- Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

### **Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) : 12
- Abemaciclib + Fulvestrant: <5
- Alpelisib + Fulvestrant: <5
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent: <5
- Atezolizumab +Nab-paclitaxel/Paclitaxel: <5
- Capecitabine as a single agent: 13
- Eribulin as a single agent or in combination: <5
- Everolimus + Exemestane: <5
- Fulvestrant as a single agent: 10
- Lapatinib : <5
- Neratinib: <5
- Parp Inhibitors (Olaparib/Talazoparib) : <5
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole): 34
- Palbociclib + Fulvestrant: 8
- Pembrolizumab: <5
- Platinum (e.g. carboplatin or cisplatin) as a single agent: <5
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) : 16
- Ribociclib + Fulvestrant: <5
- Sacituzumab Govitecan : <5
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent: <5
- Taxane and/or Anthracycline in combination: 107
- Trastuzumab as a single agent or in combination: 78
- Trastuzumab emtansine: 11
- Transtuzumab deruxtecan: <5

5 July 2023

- Any other active systemic anti-cancer therapy: Goserelin : <5, Vinorelbine: 6 & Zoledronic Acid: 13

**Q2. Does your trust participate in any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part.**

Open Breast Trials Portfolio						
Title acronym	Full Title	Date Study Opened	Current status	Planned end of recruitment	TOTAL study recruitment	Target
<b>OPTIMA</b>	OPTIMA Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (also available in the Ulster Hospital)	08/01/2018	Open	30/04/2028	35	34
<b>ROSCO</b>	Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neo-adjuvant 5-	19/06/2019	Open	Closed to recruitment 31/05/2023	<5	12
<b>SMALL</b>	A Phase III, randomised, multi-centre trial addressing overtreatment of small, screen-detected breast cancer by comparing standard surgery with minimally invasive	17/12/2019	Open	30/11/2029	27	30
<b>NOSTRA</b>	A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for	03/03/2022	Open	31/12/2023	<5	<5
<b>POETIC-A</b>	PreOperative Endocrine Therapy for Individualised Care with Abemaciclib	06/10/2022	Open	30/09/2026	5	10
<b>IMPARTE R4</b>	IMproving PAtient undeRstanding of GEP TEst Results: Phase 4	14/10/2022	Open as Patient Identification Site only	30/01/2024	<5	5
<b>RESTORE-C19</b>	Exploring the experiences and outcomes of patients not offered immediate breast Reconstruction after maSTectOmy for bREast cancer during the COVID-19	02/08/2022	Open as Patient Identification Site only	01/09/2023	N/A	N/A
Breast Trials in set-up						
Title acronym	Full Title					
<b>ATNEC</b>	Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy					
<b>HER2 Radical</b>	The HER2 RADICAL study Response Adaptive Care plan tailoring treatment for HER2 positive early breast cancer					
<b>EndoNET</b>	Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine therapy in post-menopausal women					
<b>MARECA</b>	National study of management of breast cancer locoregional recurrence and oncological outcome					
<b>VO44263</b>	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo Versus Placebo in Combination with Phesgo After First Line Induction Therapy in Participants with <b>ERCC</b> - Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer					
<b>ATNEC</b>	Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy					
<b>LION</b>	Pan Tumour Trial of Cox-Inhibitor and Immune Checkpoint Blockade					